STEPHANIE RICHETELLI: Open Payments
NPI 1700130598 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,825 in 139 payments from 22 companies in 2025. Trend: 2023 $2,268 · 2024 $2,462 · 2025 $2,825
Food & beverage: $2,825
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $627 |
| Gilead Sciences, Inc. | 21 | $424 |
| Madrigal Pharmaceuticals | 6 | $272 |
| Janssen Biotech, Inc. | 12 | $269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $234 |
| Ardelyx, Inc. | 9 | $154 |
| PFIZER INC. | 10 | $153 |
| Regeneron Healthcare Solutions, Inc. | 4 | $87 |
| GENZYME CORPORATION | 3 | $83 |
| Intercept Pharmaceuticals, Inc. | 3 | $80 |
Products named: RINVOQ, REZDIFFRA, TREMFYA, ENTYVIO, SKYRIZI, DUPIXENT, IBSRELA, XELJANZ.
Industry payments across CT — which companies pay providers there.
